Logo do repositório
 
Publicação

Adverse reactions mediated by 99mTc-tetrofosmin: Literature review and analysis of post-marketing reports

2025-12Artigo de investigação Acesso embargado
Ver registo simples
dc.contributor.authorMartins, Sara
dc.contributor.authorCosta, Sara Poças
dc.contributor.authorSousa, Mariana
dc.contributor.authorMoreira, Fernando
dc.contributor.authorMartín-Suaréz, A.
dc.contributor.authorJesus, Ângelo
dc.contributor.authorJesus, Ângelo
dc.contributor.authorMoreira, Fernando
dc.date.accessioned2026-05-12T13:17:44Z
dc.date.available2026-05-12T13:17:44Z
dc.date.issued2025-12
dc.description.abstract99mTc-tetrofosmin is a diagnostic radiopharmaceutical used to evaluate cardiac pathologies. Despite the lower incidence of reactions compared to other drugs, radiopharmaceuticals can still cause adverse reactions. For this reason, pharmacovigilance plays a crucial role in detecting, understanding, evaluating and preventing them. This study aims to review the available literature,on the safety of99mTc-tetrofosmin, and to analyze spontaneous adverse drug reaction reports from the European EudraVigilance database. A literature review was conducted according to PRISMA methodology. An analysis of spontaneous notifications was carried out in EudraVigilance, until 2022. The review identified a selection of 7 articles. The most reported adverse reactions were skin irritation, strange taste in the mouth and nausea. Regarding the EudraVigilance analysis, 220 notifications were identified, accounting for 477 adverse reactions. The majority belong to males (51%), between 18-64 years (45%). Health professionals were the main reporters (84%). The most prevalent System Organ Class was “general disorders and administration site conditions” (21%) and the most reported adverse reaction was pruritus (10%). Approximately 67% of reactions were considered serious, with 6 fatal cases recorded. The results demonstrated that adverse reactions associated with99mTc-tetrofosmin do occur and should not be minimized. Over a period of 17 years, only 220 notifications were recorded, which may highlight potential challenges in pharmacovigilance for radiopharmaceuticals. Therefore, raising awareness about the importance of reporting adverse reactions is crucial.eng
dc.identifier.citationMartins, S., Costa, S., Sousa, M., Moreira, F., Martín-Suaréz, A., & Jesus, Â. (2025). Adverse reactions mediated by 99mTc-tetrofosmin: Literature review and analysis of post-marketing reports. Revista Española de Medicina Nuclear e Imagen Molecular, 44(6), 500166. https://doi.org/10.1016/j.remn.2025.500166
dc.identifier.doi10.1016/j.remnie.2025.500166
dc.identifier.urihttp://hdl.handle.net/10400.22/32355
dc.language.isoeng
dc.peerreviewedyes
dc.publisherElsevier España
dc.relationUID/50006
dc.relation.hasversionhttps://www.sciencedirect.com/science/article/abs/pii/S2253654X25000642?via%3Dihub
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectPharmacovigilance
dc.subjectAdverse drug reactions
dc.subjectRadiopharmaceuticals
dc.subject99mTc-tetrofosmin
dc.subjectMyocardial perfusion scintigraphy
dc.titleAdverse reactions mediated by 99mTc-tetrofosmin: Literature review and analysis of post-marketing reportseng
dc.title.alternativeReacciones adversas mediadas por [99mTc]Tc-tetrofosmina: revisión de la literatura y análisis de informes poscomercializaciónspa
dc.typeresearch article
dspace.entity.typePublication
oaire.citation.issue6
oaire.citation.titleRevista Española de Medicina Nuclear e Imagen Molecular
oaire.citation.volume44
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85
person.familyNameJesus
person.familyNameMoreira
person.givenNameÂngelo
person.givenNameFernando
person.identifier2947760
person.identifier.ciencia-idA91F-3585-4F42
person.identifier.ciencia-id5F16-AB92-94D0
person.identifier.orcid0000-0003-3972-8253
person.identifier.orcid0000-0002-3452-1459
person.identifier.ridA-4404-2012
person.identifier.scopus-author-id56153841300
relation.isAuthorOfPublication1cbff3da-9800-4bd7-8d84-fd8d9ca819b2
relation.isAuthorOfPublication81213e80-09a5-4655-93dc-e54199edb2fe
relation.isAuthorOfPublication.latestForDiscovery1cbff3da-9800-4bd7-8d84-fd8d9ca819b2

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
ART_Sara Martins.pdf
Tamanho:
608.66 KB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
4.03 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

ESS - CISA/LAQV Requimte - Artigos
ESS - FAR - Artigos